Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Isenberg

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRILCaroline Gordon, David Wofsy, Stephen Wax, et al.
Rheumatology (Oxford, England)|November 22, 2020
Fracture risk in systemic lupus erythematosus patients over 28 yearsDaniela Garelick, Sara Moreira Pinto, Filipa Farinha, et al.
Arthritis Research & Therapy|January 12, 2005
The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipinIan Giles, Nancy Lambrianides, David Latchman, et al.
Arthritis and Rheumatism|December 30, 2009
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trialEllen M Ginzler, David Wofsy, David Isenberg, et al.
Seminars in Arthritis and Rheumatism|May 18, 2023
Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-upNicola Farina, Jemma Webster, Weike Luo, et al.
Rheumatology (Oxford, England)|September 20, 2013
The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online surveyCaroline Gordon, David Isenberg, Kirsten Lerstrøm, et al.
Annals of the Rheumatic Diseases|March 30, 2019
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosusChris Wincup, Madhvi Menon, Edward Smith, et al.
Best Practice & Research. Clinical Rheumatology|February 22, 2024
Clinical patterns of disease: From early systemic lupus erythematosus to late-onset diseaseMatteo Piga, Kostantinos Tselios, Luísa Viveiros, et al.
Rheumatology (Oxford, England)|April 30, 2010
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohortsThórunn Jónsdóttir, Iva Gunnarsson, Ana Filipa Mourão, et al.
Lupus|May 6, 2026
Morbidity and mortality in primary versus secondary antiphospholipid syndrome: A single-center study using the 2023 ACR/EULAR criteriaRoni Meidan, Monica Angerri Nadal, Blanca Viejo Sosa, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRILCaroline Gordon, David Wofsy, Stephen Wax, et al.
Rheumatology (Oxford, England)|November 22, 2020
Fracture risk in systemic lupus erythematosus patients over 28 yearsDaniela Garelick, Sara Moreira Pinto, Filipa Farinha, et al.
Arthritis Research & Therapy|January 12, 2005
The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipinIan Giles, Nancy Lambrianides, David Latchman, et al.
Arthritis and Rheumatism|December 30, 2009
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trialEllen M Ginzler, David Wofsy, David Isenberg, et al.
Seminars in Arthritis and Rheumatism|May 18, 2023
Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-upNicola Farina, Jemma Webster, Weike Luo, et al.
Rheumatology (Oxford, England)|September 20, 2013
The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online surveyCaroline Gordon, David Isenberg, Kirsten Lerstrøm, et al.
Annals of the Rheumatic Diseases|March 30, 2019
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosusChris Wincup, Madhvi Menon, Edward Smith, et al.
Best Practice & Research. Clinical Rheumatology|February 22, 2024
Clinical patterns of disease: From early systemic lupus erythematosus to late-onset diseaseMatteo Piga, Kostantinos Tselios, Luísa Viveiros, et al.
Rheumatology (Oxford, England)|April 30, 2010
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohortsThórunn Jónsdóttir, Iva Gunnarsson, Ana Filipa Mourão, et al.
Lupus|May 6, 2026
Morbidity and mortality in primary versus secondary antiphospholipid syndrome: A single-center study using the 2023 ACR/EULAR criteriaRoni Meidan, Monica Angerri Nadal, Blanca Viejo Sosa, et al.
Pageof 19